<DOC>
	<DOCNO>NCT00772148</DOCNO>
	<brief_summary>The purpose study demonstrate pharmacokinetics ( PK , measure amount medication blood sample ) safety new medicine , LCP-Tacro™ tablet , Prograf® capsule , drug commonly take transplant recipient prevent body reject transplanted kidney liver . LCP-Tacro tablet contain active ingredient ( tacrolimus ) Prograf capsule , tablet design release tacrolimus extend period take daily . LCP-Tacro investigational drug . This study evaluate level tacrolimus blood first two week liver transplant patient randomly assign ( chance , like flip coin ) take either LCP-Tacro™ tablet ( tacrolimus ) daily Prograf® capsule twice daily . In addition , patient remain study drug 360 day order evaluate relative safety LCP-Tacro™ tablet compare Prograf longer period time .</brief_summary>
	<brief_title>Pharmacokinetics LCP-Tacro™ Once Daily Prograf® Twice A Day Adult De Novo Liver Transplant Patients</brief_title>
	<detailed_description>This randomize , parallel-group , open-label , multicenter study adult de novo liver transplant patient demonstrate pharmacokinetics safety once-daily treatment LCP-Tacro tablet twice-daily Prograf capsule first 2 week live transplantation . The study also compare efficacy safety LCP-Tacro Prograf additional 50 week liver transplantation . Eligible patient randomize ( 1:1 ratio ) within 72 hour transplantation ( graft reperfusion ) receive either : 1 ) LCP-Tacr tablet orally daily ( QD ) morning , interval 24 +/- 1 hour dose , start 0.07 0.11 mg/kg ( start daily dose African-American patient 0.09 0.13 mg/kg ) , 2 ) Prograf capsule 2 equally divided morning evening dos , start 0.10 0.15 mg . Subsequent dos study medication adjust investigator accord local practice maintain target whole blood tacrolimus trough level 5 20 ng/mL think Day 14 . Twenty-four-hour pharmacokinetic assessment perform Days 1 , 7 14 ; additionally whole blood tacrolimus trough level statistical analysis measure Days 2 , 3 , 4 , 7 , 10 , 12 , 12 , 42 , 90 , 120 , 180 , 270 , 360 . Physicians could also perform tacrolimus trough level time discretion . On Day 360 , patient place maintenance immunosuppressive regimen determine treat physician . Following completion third final pharmacokinetic assessment Day 14 , patient enter maintenance phase ( Days 15 360 ) study remain assigned study medication Day 360 . Visits safety assessment tacrolimus trough level maintenance phase Days 42 , 90 , 120 , 180 , 270 360 . Immunosuppressive therapy conclusion study administer discretion patient 's population .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Adult men woman least 18 year age recipients liver transplant decease donor Model EndStage Liver Disease ( MELD ) score time transplantation ≤ 30 able give inform consent participation Recipient transplant organ liver Recipients liver nonheart beat donor Recipients liver ABO incompatible donor Recipients bone marrow stem cell transplant Patients white blood cell count ≤ 2.8 x 109/L unless absolute neutrophil count ( ANC ) &gt; 1.0 x 109/L Patients fail drug abuse screen pretransplant evaluation Patients unable swallow study medication Patients incapable understanding purpose risk study , give write informed consent , unwilling comply study protocol Pregnant nursing woman ( woman childbearing potential must negative serum pregnancy test within seven day prior receive study medication ) Patients reproductive potential unwilling/unable use double barrier method contraception throughout duration study Patients treat investigational agent 30 day prior enrollment Patients seropositive human immunodeficiency virus ( HIV ) Patients current malignancy history malignancy ( within past 5 year ) , except basal nonmetastatic squamous cell carcinoma skin treat successfully , hepatocellular carcinoma ( HCC ) meet Milan Criteria liver transplantation Patients uncontrolled concomitant infection , systemic infection require treatment , unstable medical condition could interfere study objective Patients severe diarrhea , vomit , active peptic ulcer gastrointestinal disorder may affect absorption tacrolimus Patients know hypersensitivity tacrolimus Patients form current substance abuse , psychiatric disorder condition , opinion Investigator , may invalidate communication Investigator Randomization one two treatment group do post transplantation provide patient fulfills follow additional criterion : Patient able receive first dose randomized study drug orally within 72 hour transplant surgery ( graft reperfusion ) Patient NOT give intravenous tacrolimus prior first oral dose study medication Recipient liver cold ischemia time ≤ 10 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Liver</keyword>
	<keyword>Hepatic</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
</DOC>